Clinical Trial Update: A Phase II Study of Allo-HCT for B-Cell NHL Using Zevalin, Fludarabine and Melphalan [Phase 2]

View source ↗

Summary

Phase II trial evaluating allogeneic hematopoietic cell transplantation for B-cell non-Hodgkin lymphoma using Zevalin, fludarabine, and melphalan; study complet…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Non-hodgkin Lymphoma
• Graft-versus-host Disease
• Leukemia

Drugs mentioned

• Fludarabine (Fludarabine)
• Melphalan (Melphalan)
• Zevalin (ibritumomab tiuxetan)

Snippet

Sponsor: City of Hope Medical Center | Conditions: Graft Versus Host Disease, Leukemia | Phase 2 | Status: COMPLETED | Results posted: 2022-12-23